Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568350 | 0.87 | MLYCD (0.49) | HDAC1HDAC6MLYCDLMNAHTT | |
| SCHEMBL2883042 | 0.86 | CES2 (0.52) | MLYCDKCNQ3KCNQ2LMNAHTT | |
| SCHEMBL4843412 | 0.84 | MLYCD (0.49) | MLYCDLMNAHTTRAB9AALDH1A1 | |
| SCHEMBL20982579 | 0.83 | MLYCD (0.49) | MLYCDMTORLMNAHTTMAPK1 | |
| SCHEMBL16905393 | 0.82 | HDAC1 (0.58) | HDAC1HDAC6MTORKCNQ3KCNQ2 | |
| SCHEMBL29797355 | 0.82 | HTT (0.63) | MLYCDKCNQ3KCNQ2LMNAHTT | |
| SCHEMBL4822355 | 0.82 | HTT (0.63) | MLYCDKCNQ3KCNQ2LMNAHTT | |
| SCHEMBL589423 | 0.82 | MLYCD (0.48) | HDAC1HDAC6MLYCDLMNAHTT | |
| SCHEMBL5775088 | 0.80 | MLYCD (0.45) | MLYCDMTORHTTALDH1A1KMT2A | |
| SCHEMBL760870 | 0.80 | MLYCD (0.49) | MLYCDLMNATRPM8ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| US-20170258800-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE HOLDINGS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20150148348-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2015-05-28 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8901123-B2 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | INCYTE CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130289036-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8420645-B2 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | INCYTE CORPORATION | 2009-11-26 | — | — | US | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148348-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | HDAC1 1442/4885HDAC6 499/4885MLYCD 1623/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | HDAC1 831/4885HDAC6 1685/4885MLYCD 2833/4885 |
| US-20130289036-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | HDAC1 1442/4885HDAC6 499/4885MLYCD 1623/4885 |
| US-20090291956-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | HDAC1 1442/4885HDAC6 499/4885MLYCD 1623/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | HDAC1 64/4885HDAC6 351/4885MLYCD 3764/4885 |
| US-20170258800-A1 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME | ABL1, MET, ABL2 | HDAC1 1442/4885HDAC6 499/4885MLYCD 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.